Bristol Myers Squibb (BMY) Q3 2026: Revenue Growth and Guidance Raise — Positive Outlook

Bristol Myers Squibb (NYSE: BMY) reported its third-quarter financial results for 2026, showcasing a revenue increase of $0.9 billion or +7% year-over-year, reaching a total of $13.1 billion. This performance reflects the company's strong execution and growth in its portfolio, particularly in its Growth Portfolio, which saw a revenue increase of $0.8 billion or +12% to $7.7 billion.

This quarter's results are a positive development for shareholders, as the company not only achieved revenue growth but also raised its full-year revenue guidance. The updated guidance now stands at a range of $49.75 billion to $50.25 billion, up from previous estimates, indicating strong momentum across its product offerings.

Key Financial Metrics:

• Total Revenues: $13.1 billion, up $0.9 billion or +7% YoY
• Growth Portfolio Revenues: $7.7 billion, up $0.8 billion or +12% YoY
• GAAP EPS: $1.05, down from $1.08, a decrease of -3%
• Non-GAAP EPS: $1.35, down from $1.63, a decrease of -17%
• U.S. Revenues: $9.1 billion, up +9%
• International Revenues: $4.0 billion, up +3% (or +4% Ex-FX)

Analysis and Opinion

The quarter's performance is commendable, particularly given the challenges faced in the pharmaceutical industry. The 7% revenue growth, driven by a robust 12% increase in the Growth Portfolio, demonstrates Bristol Myers Squibb's effective strategy in expanding its market presence and product offerings. The company’s ability to maintain a strong revenue trajectory, despite a slight decline in EPS figures, indicates resilience and operational efficiency.

The decrease in GAAP and non-GAAP EPS can be attributed to the net impact of $(0.58) from Acquired IPRD charges and licensing income, which reflects ongoing investments in innovation and pipeline development. While the EPS figures are lower than the previous year, the overall revenue growth and guidance raise suggest that the company is on a solid path to recovery and growth.

Dividend and Share Buyback

There were no announcements regarding dividends or share buybacks in this quarter's report. However, the focus on strengthening the balance sheet and investing in growth initiatives suggests that the company is prioritizing long-term value creation over immediate shareholder returns.

Forward Guidance and Catalysts

Bristol Myers Squibb has raised its full-year revenue guidance to a range of $49.75 billion to $50.25 billion, reflecting confidence in its product pipeline and market dynamics. The updated non-GAAP EPS guidance is now set at $6.35 to $6.55, inclusive of a $(0.60) per share impact from Acquired IPRD charges and licensing income.

Investors should closely monitor upcoming pipeline milestones and regulatory approvals, particularly for products like Zenbexus, which has shown promising results in clinical trials. The company’s commitment to expanding its manufacturing capabilities in the U.S. and investing in next-generation medicines will also be critical to watch as these initiatives could significantly impact future revenue growth.

In summary, Bristol Myers Squibb's Q3 2026 results reflect a strong operational performance and a positive outlook for the remainder of the year, making it a favorable time for shareholders to remain optimistic about the company's trajectory.

BRISTOL-MYERS SQUIBB COMPANY - CONSOLIDATED STATEMENTS OF EARNINGS

(Unaudited, dollars and shares in millions except per share data)

	2026	2025	2026	2025
	Three Months	Three Months	Nine Months	Nine Months
Net product sales	$ 12,606	$ 11,850	$ 36,362	$ 34,645
Allian...	$ 463	$ 372	$ 1,169	$ 1,047
Total Revenue	$ 13,069	$ 12,222	$ 37,532	$ 35,692
Cost of produc...	$ 4,146	$ 3,435	$ 11,292	$ 9,839
Sellin...	$ 1,699	$ 1,789	$ 5,142	$ 5,086
Resear...	$ 2,365	$ 2,528	$ 7,973	$ 7,365
Acquir...	$ 1,558	$ 633	$ 1,651	$ 2,328
Amorti...	$ 458	$ 831	$ 1,332	$ 2,491
Total Expense	$ 10,533	$ 9,108	$ 27,670	$ 27,834
Net Earnings	$ 2,162	$ 2,195	$ 8,156	$ 5,970
Net Earnings Attrib...	$ 2,162	$ 2,201	$ 8,156	$ 5,967
Basic	$ 2,043	$ 2,036	$ 2,041	$ 2,034
Diluted	$ 2,053	$ 2,039	$ 2,049	$ 2,039
Earnin... per Common Share:	Basic: $ 1.06	$ 1.08	$ 4.00	$ 2.93
Diluted	$ 1.05	$ 1.08	$ 3.98	$ 2.93
Other (incom... expense	$ 403	$ 480	$ 1,220	$ 1,459
Royalty income	$ —	$ -286	$ —	$ -844
Royalty income - divest...	$ -200	$ -276	$ -580	$ -697
Invest... income	$ -118	$ -161	$ -323	$ -438
Provis... for restruc...	$ 187	$ 75	$ 247	$ 432
Litiga... and other settle...	$ 3	$ 165	$ 11	$ 424
Contin... consid...	$ —	$ —	$ —	$ 336
Equity invest... (gains... net)	$ 26	$ -190	$ -222	$ -90
Integr... expens...	$ 10	$ 36	$ 46	$ 110
Divest... (gains... net)	$ —	$ 8	$ -162	$ 1
Other	$ -4	$ 40	$ 41	$ 33
Other (incom... net)	$ 307	$ -108	$ 279	$ 725

BRISTOL-MYERS SQUIBB COMPANY - CONSOLIDATED BALANCE SHEETS

(Unaudited, dollars in millions)

	September 30, 2026	December 31, 2025
Cash and cash equivalents	$ 9,574	$ 10,209
Marketable debt securities - current	$ 3,007	$ 464
Marketable debt securities - non-current	$ 378	$ 396
Cash, cash equivalents and marketable debt securities	$ 12,959	$ 11,069
Short-term debt obligations	$ -1,028	$ -2,261
Long-term debt	$ -41,849	$ -42,850
Net debt position	$ -29,918	$ -34,043

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.